Posted by Michael Wonder on 08 Dec 2022
Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
8 December 2022 - The decision by the Italian AIFA provides highly sensitised patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.
Hansa Biopharma today announces that the Italian Medicine Agency (AIFA) has granted full access and reimbursement for the use of Idefirix, the company's first in class treatment, for the desensitisation of highly sensitised adult patients prior to kidney transplant from a deceased donor.
